Post-Traumatic Stress Disorder (PTSD) - Epidemiology Forecast - 2032

Post-Traumatic Stress Disorder (PTSD) - Epidemiology Forecast - 2032

DelveInsight's "" Post-traumatic stress disorder (PTSD) - Epidemiology Forecast-2032"" report delivers an in-depth understanding of the Post-traumatic stress disorder (PTSD), historical and forecasted epidemiology as well as the Post-traumatic stress disorder (PTSD) trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

  • Study Period: 2019-2032

    Post-traumatic stress disorder (PTSD) Understanding

    The DelveInsight's Post-traumatic stress disorder (PTSD) epidemiology report gives a thorough understanding of Post-traumatic stress disorder (PTSD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Post-traumatic stress disorder (PTSD) has been described as “the complex somatic, cognitive, affective, and behavioral effects of psychological trauma.” It is characterized by intrusive thoughts, nightmares, and flashbacks of past traumatic events, avoidance of reminders of trauma, hypervigilance, and sleep disturbance, all of which lead to considerable social, occupational, and interpersonal dysfunction.

    PTSD symptoms may start within 1 month of a traumatic event, but sometimes symptoms may not appear until years after the event. These symptoms cause significant problems in social or work situations and relationships. They can also interfere with the ability to go about the normal daily tasks, and the symptoms are generally grouped into four types: intrusive memories, avoidance, negative changes in thinking and mood, and changes in physical and emotional reactions. Symptoms can vary over time or vary from person to person. Patients can develop PTSD when they go through, see or learn about an event involving actual or threatened death, serious injury, or sexual violation. Several factors can play a role in how people respond to traumatic events. Genetics, for example, can influence how people handle stress during and after a trauma. People may be more likely to develop PTSD if they also have an existing mental health condition, have experienced trauma in the past, face other life stressors, and lack social support.

    Diagnosis

    PTSD is not diagnosed until at least one month has passed since the traumatic event happened. If symptoms of PTSD are present, the doctor will begin an evaluation by performing a complete medical history and physical exam. Although there are no lab tests to diagnose PTSD specifically, the doctor may use various tests to rule out physical illness as the cause of the symptoms. If no physical illness is found, one may be referred to a psychiatrist, psychologist, or other mental health professionals specially trained to diagnose and treat mental illnesses. Psychiatrists and psychologists use specially designed interview and assessment tools to evaluate a person for the presence of PTSD or other psychiatric conditions. The doctor bases their diagnosis of PTSD on reported symptoms, including any problems with functioning caused by the symptoms. The doctor then determines if the symptoms and degree of dysfunction indicate PTSD. PTSD is diagnosed if the person has symptoms of PTSD that last for more than 1 month.

    Post-traumatic stress disorder (PTSD) Epidemiology

    The epidemiology section provides insights about the historical and current Post-traumatic stress disorder (PTSD) patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

    Key Findings

    The disease epidemiology covered in the report provides historical as well as forecasted Post-traumatic stress disorder (PTSD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

    In the year 2021, the total diagnosed prevalent cases of Post-traumatic stress disorder (PTSD) was 5,340,957 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

    The disease epidemiology covered in the report provides historical as well as forecasted Post-traumatic stress disorder (PTSD) epidemiology [segmented as Prevalent population Cases of PTSD, Diagnosed prevalent cases of PTSD, Gender-specific cases of PTSD, Severity-Specific cases of PTSD, Age-specific cases of PTSD and Total Treated Cases of PTSD] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

    Country Wise- Post-traumatic stress disorder (PTSD) Epidemiology

    The epidemiology segment also provides the Post-traumatic stress disorder (PTSD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

    KOL- Views

    To keep up with the current Post-traumatic stress disorder (PTSD) patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the Post-traumatic stress disorder (PTSD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.

    Scope of the Report
  • The report covers the descriptive overview of Post-traumatic stress disorder (PTSD), explaining their causes, symptoms, pathophysiology, and genetic basis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Post-traumatic stress disorder (PTSD).
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM by Prevalent population Cases of PTSD, Diagnosed prevalent cases of PTSD, Gender-specific cases of PTSD, Severity-Specific cases of PTSD, Age-specific cases of PTSD and Total Treated Cases of PTSD

  • Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Post-traumatic stress disorder (PTSD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Post-traumatic stress disorder (PTSD)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

  • Post-traumatic stress disorder (PTSD) Report Key Strengths
  • 11 Years Forecast
  • 7MM Coverage
  • Post-traumatic stress disorder (PTSD) Epidemiology Segmentation

  • Key Questions

    Epidemiology Insights:
  • What are the disease risk, burden, and regional/ethnic differences of Post-traumatic stress disorder (PTSD)?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Post-traumatic stress disorder (PTSD) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Post-traumatic stress disorder (PTSD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM concerning the patient population about Post-traumatic stress disorder (PTSD)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Post-traumatic stress disorder (PTSD) during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

  • Reasons to buy
  • The report will help in developing business strategies by understanding trends shaping and driving the Post-traumatic stress disorder (PTSD) Disease market
  • To understand the future market competition in the Post-traumatic stress disorder (PTSD) Disease market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Post-traumatic stress disorder (PTSD) Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Post-traumatic stress disorder (PTSD) Disease market
  • To understand the future market competition in the Post-traumatic stress disorder (PTSD) Disease market

  • 1. Key Insights
    2. Report Introduction
    3. Post-traumatic stress disorder Market Overview at a Glance
    3.1. Market Share (%) Distribution of Post-traumatic stress disorder in 2019
    3.2. Market Share (%) Distribution of Post-traumatic stress disorder in 2032
    4. Executive Summary of Post-traumatic Stress Disorder (PTSD)
    4.1. Key Events
    5. Epidemiology and Market Methodology
    6. Disease Background and Overview
    6.1. Introduction
    6.2. Causes of Post-traumatic Stress Disorder
    6.3. Risk Factors of Post-traumatic Stress Disorder
    6.4. Signs and Symptoms of Post-traumatic Stress Disorder
    6.5. Clinical Manifestations of Post-traumatic Stress Disorders
    6.6. Pathophysiology of Post-traumatic Stress Disorder
    6.7. Medications
    6.8. Comorbidities of Post-traumatic Stress Disorder
    7. Diagnosis of Post-traumatic Stress Disorder
    7.1. Diagnostic Criteria
    7.2. Diagnostic Algorithm of Post-traumatic disorder
    7.3. The Differential Diagnosis of Post-traumatic Stress Disorder
    8. Treatment of Post-traumatic Stress Disorder
    8.1. Psychotherapy
    8.2. Treatment Algorithm
    9. Diagnosis and Treatment Guidelines
    9.1. American Psychological Association
    9.2. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-compulsive, and Post-traumatic Stress Disorders
    9.3. World Health Organization Guidelines for the Management of Conditions Specifically Related to PTSD 2013
    9.4. NICE Guidelines for Post-traumatic Stress Disorder (2018)
    9.5. VA/DOD Clinical Practice Guideline for the Management of Post-traumatic Stress Disorder and Acute Stress Disorder (2017)
    10. Conclusion
    11. Epidemiology and Patient Population
    11.1. Key Findings
    11.2. Epidemiology Scenario
    11.2.1. Prevalence population of Post-traumatic stress disorder
    11.2.2. Diagnosed prevalent Cases of Post-traumatic stress disorder
    11.2.3. Gender-specific Cases of Post-traumatic stress disorder
    11.2.4. Severity-specific Cases of Post-traumatic stress disorder
    11.2.5. Age-specific Cases of Post-traumatic stress disorder
    11.2.6. Total Treated Cases of Post-traumatic stress disorder
    12. Appendix
    12.1. Bibliography
    12.2. Report Methodology
    13. DelveInsight Capabilities
    14. Disclaimer
    15. About DelveInsight

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings